JAZZ - Jazz Pharmaceuticals plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
137.62
+1.01 (+0.74%)
At close: 4:00PM EDT

137.62 0.00 (0.00%)
After hours: 4:15PM EDT

Stock chart is not supported by your current browser
Previous Close136.61
Open136.95
Bid137.58 x 800
Ask137.59 x 1100
Day's Range135.86 - 138.22
52 Week Range113.52 - 181.46
Volume260,924
Avg. Volume503,858
Market Cap7.849B
Beta (3Y Monthly)1.02
PE Ratio (TTM)17.10
EPS (TTM)8.05
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est171.63
Trade prices are not sourced from all markets
  • 3 Incredibly Cheap Healthcare Stocks
    Motley Fool3 days ago

    3 Incredibly Cheap Healthcare Stocks

    Looking for bargains? You'll definitely want to check out these dirt-cheap healthcare stocks.

  • Jazz Pharmaceuticals signs multimillion-dollar deal for experimental cancer therapy
    American City Business Journals7 days ago

    Jazz Pharmaceuticals signs multimillion-dollar deal for experimental cancer therapy

    Jazz is paying $3.5 million up front, and another $203 million in contingent payments tied to hitting product development milestones, for an England company's cancer therapy program.

  • Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset
    Zacks7 days ago

    Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset

    Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.

  • Benzinga7 days ago

    The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 9) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Athenex ...

  • PR Newswire7 days ago

    Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma

    Pan-RAF Program adds an Early Stage, Innovative, Precision Oncology Asset to Jazz Pharmaceuticals' Growing R&D Portfolio Redx to Receive $3.5 Million Upfront, up to $203 Million in Milestone Payments and ...

  • Do You Know What Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) P/E Ratio Means?
    Simply Wall St.12 days ago

    Do You Know What Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) P/E Ratio Means?

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at...

  • ETF & Stock Winners of Longest US Economic Expansion
    Zacks14 days ago

    ETF & Stock Winners of Longest US Economic Expansion

    The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.

  • PR Newswire22 days ago

    Jazz Pharmaceuticals Announces Webcast for Sunosi Investor Update

    DUBLIN, June 25, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the company will host a webcast on Tuesday, July 2, 2019 at 4:30 p.m. EDT/9:30 p.m. IST to provide investors with an update on Sunosi™ (solriamfetol), which was approved by the U.S. Food and Drug Administration on March 20, 2019 to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).  Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved to treat excessive daytime sleepiness in adults living with narcolepsy or OSA.  Beginning early July, Sunosi will be commercially available in the U.S. following the recent scheduling decision by the U.S. Drug Enforcement Agency. A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

  • JAZZ or PCRX: Which Is the Better Value Stock Right Now?
    Zacks23 days ago

    JAZZ or PCRX: Which Is the Better Value Stock Right Now?

    JAZZ vs. PCRX: Which Stock Is the Better Value Option?

  • Philadelphia location is fueling Jazz Pharmaceuticals' job growth
    American City Business Journals26 days ago

    Philadelphia location is fueling Jazz Pharmaceuticals' job growth

    Last August, while showing off his company’s expanded Philadelphia office space, Jazz Pharmaceuticals President and COO Dan Swisher said he wouldn’t be surprised to see the company’s Center City headcount top 200 by 2020. Jazz has already surpassed that mark, and then some. “We have 220 people in Philadelphia and another 20 open positions,” said Bruce Cozadd, the company’s co-founder, chairman and CEO.

  • Here’s What Hedge Funds Think About Jazz Pharmaceuticals Public Limited Company (JAZZ)
    Insider Monkey27 days ago

    Here’s What Hedge Funds Think About Jazz Pharmaceuticals Public Limited Company (JAZZ)

    Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]

  • Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
    Zacks29 days ago

    Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

    Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.

  • Markit29 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for JAZZ with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding JAZZ are favorable, with net inflows of $3.31 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswirelast month

    Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol)

    DUBLIN, June 17, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the U.S. Drug Enforcement Agency (DEA) has designated solriamfetol, also known as Sunosi, as a Schedule IV medicine. With U.S. Food and Drug Administration (FDA) approval on March 20, 2019, Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

  • Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
    Zackslast month

    Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Simply Wall St.last month

    Should You Worry About Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Pay?

    In 2009 Bruce Cozadd was appointed CEO of Jazz Pharmaceuticals plc (NASDAQ:JAZZ). First, this article will compare CEO...

  • Why Is Jazz (JAZZ) Down 7.3% Since Last Earnings Report?
    Zackslast month

    Why Is Jazz (JAZZ) Down 7.3% Since Last Earnings Report?

    Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • JAZZ or ZTS: Which Is the Better Value Stock Right Now?
    Zackslast month

    JAZZ or ZTS: Which Is the Better Value Stock Right Now?

    JAZZ vs. ZTS: Which Stock Is the Better Value Option?

  • PR Newswirelast month

    Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development

    DUBLIN, June 3, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced the appointment of Robert Iannone, M.D., M.S.C.E., as executive vice president, research and development, effective May 29, 2019. Dr. Iannone will lead Jazz's growing global R&D organization, including the pre-clinical development, clinical development, clinical operations, biostatistics, medical affairs, regulatory affairs, pharmacovigilance and safety functions. "Rob's extensive industry knowledge, leadership experience and strategic insights bring expertise in areas critical to our expanding capabilities as an innovative, global biopharmaceutical company with growing R&D investment and portfolio," said Daniel Swisher, president and chief operating officer at Jazz Pharmaceuticals.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 30) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Misonix, ...

  • Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason
    Zacks2 months ago

    Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason

    Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason